MDT

88.01

+0.07%↑

A

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

A

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

A

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

A

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

MDT

88.01

+0.07%↑

A

120.5

+2.55%↑

VEEV

158.62

+0.08%↑

HQY

81.13

+1.58%↑

TLRY

6.92

+3.13%↑

Search

Boston Scientific Corp.

Затворен

СекторЗдравеопазване

63.81 1.25

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

63.07

Максимум

64.47

Ключови измерители

By Trading Economics

Приходи

-83M

672M

Продажби

221M

5.3B

P/E

Средно за сектора

32.263

66.418

Марж на печалбата

12.713

Служители

59,000

EBITDA

-412M

956M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+59.15% upside

Дивиденти

By Dow Jones

Следващи печалби

22.04.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-43B

93B

Предишно отваряне

62.56

Предишно затваряне

63.81

Настроения в новините

By Acuity

57%

43%

296 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Boston Scientific Corp. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.02.2026 г., 16:14 ч. UTC

Печалби
Значими двигатели на пазара

Boston Scientific Plunges on Disappointing 1Q Outlook Despite 4Q Earnings Beat

4.02.2026 г., 12:13 ч. UTC

Печалби

Boston Scientific Sees More Growth after Earnings, Sales Rise

15.01.2026 г., 13:29 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- 2nd Update

15.01.2026 г., 12:35 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock -- Update

15.01.2026 г., 12:29 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific to Buy Penumbra for $15 Billion in Cash, Stock

30.03.2026 г., 15:34 ч. UTC

Пазарно говорене

Boston Scientific Faces Some Slowing Growth Trends -- Market Talk

4.02.2026 г., 21:41 ч. UTC

Печалби

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4.02.2026 г., 19:38 ч. UTC

Печалби

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4.02.2026 г., 17:32 ч. UTC

Печалби

These Stocks Are Today's Movers: AMD, AbbVie, Eli Lilly, Boston Scientific, MP Materials, Super Micro, Silicon Labs, Uber, and More -- Barrons.com

4.02.2026 г., 15:30 ч. UTC

Печалби

Boston Scientific Earnings Beat Estimates. It's the Worst Stock in the S&P 500 Today. -- Barrons.com

4.02.2026 г., 15:29 ч. UTC

Печалби

These Stocks Are Today's Movers: AMD, Eli Lilly, AbbVie, Uber, Super Micro, Enphase, Boston Scientific, and More -- Barrons.com

4.02.2026 г., 14:06 ч. UTC

Печалби

Boston Scientific Profit, Sales Rise but Issues Soft Guidance -- Update

4.02.2026 г., 13:58 ч. UTC

Печалби

Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com

4.02.2026 г., 13:12 ч. UTC

Печалби

Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com

4.02.2026 г., 11:32 ч. UTC

Печалби

Boston Scientific Sees 2026 Sales Up 10.5%-11.5%, Organic Sales Up 10%-11% >BSX

4.02.2026 г., 11:31 ч. UTC

Печалби

Boston Scientific Sees 1Q Sales Up 10.5%-12%, Organic Sales Up 8.5%-10% >BSX

4.02.2026 г., 11:30 ч. UTC

Печалби

Boston Scientific 4Q Organic Sales Up 12.7% >BSX

4.02.2026 г., 11:30 ч. UTC

Печалби

Boston Scientific Sees 2026 Adj EPS $3.43-Adj EPS $3.49 >BSX

4.02.2026 г., 11:30 ч. UTC

Печалби

Boston Scientific Sees 1Q Adj EPS 78c-Adj EPS 80c >BSX

4.02.2026 г., 11:30 ч. UTC

Печалби

Boston Scientific 4Q Adj EPS 80c >BSX

4.02.2026 г., 11:30 ч. UTC

Печалби

Boston Scientific 4Q Sales $5.29B >BSX

4.02.2026 г., 11:30 ч. UTC

Печалби

Boston Scientific 4Q EPS 45c >BSX

24.01.2026 г., 06:18 ч. UTC

Придобивния, сливания и поглъщания

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock. -- Barrons.com

15.01.2026 г., 14:37 ч. UTC

Горещи акции

Stocks to Watch Thursday: Goldman Sachs, Boston Scientific, BlackRock -- WSJ

15.01.2026 г., 13:45 ч. UTC

Придобивния, сливания и поглъщания

Penumbra Stock Jumps. It's Being Bought by Boston Scientific for $14.5 Billion. -- Barrons.com

15.01.2026 г., 12:04 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific: Penumbra Shareholders Can Elect to Receive Cash or Stock >BSX PEN

15.01.2026 г., 12:03 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific: Acquisition to Expand Cardiovascular Portfolio >BSX PEN

15.01.2026 г., 12:01 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific: Penumbra Deal Carriers an Enterprise Value of About $14.5 Billion >BSX

15.01.2026 г., 12:00 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific to Buy Penumbra for $374/Share >BSX PEN

15.01.2026 г., 12:00 ч. UTC

Придобивния, сливания и поглъщания

Boston Scientific Announces Agreement To Acquire Penumbra, Inc. >BSX PEN

Сравнение с други в отрасъла

Ценова промяна

Boston Scientific Corp. Прогноза

Ценова цел

By TipRanks

59.15% нагоре

12-месечна прогноза

Среден 100.55 USD  59.15%

Висок 124 USD

Нисък 80 USD

Според 25 анализатори от Wall Street, предложили 12-месечна ценова цел за Boston Scientific Corp. през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

25 ratings

24

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

102.95 / 104.93Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Weak Bearish Evidence

Дългосрочен план

No Evidence

Настроение

By Acuity

296 / 348 Класиране в Здравеопазване

Настроения в новините

Мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat